Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
EPIC: IPA
Market: TSX-V
52-week High/Low: C$1.56 / C$0.49
Sector: Pharma & Biotech
Market Cap: C$20.45M
Immunoprecise Antibodies Ltd

Immunoprecise Antibodies Ltd

ImmunoPrecise Antibodies Ltd. is a public company listed on the TSX Venture Exchange (TSXV: IPA) located in Victoria, British Columbia, Canada and preeminent supplier of custom antibodies to the global research industry and industrial community. Our dedication to advancing antibody development has resulted in cutting-edge immunological innovations. With over 25 years of experience in the custom antibody business, IPA provides high customer satisfaction through a customized professional approach.

Immunoprecise Antibodies Ltd

immunoprecise.com

Interactive graph

col 3
col 4
col 5
col 6

Immunoprecise Antibodies Ltd Snapshot

Since its inception in 1989, IPA has been serving clinical research and biological markets worldwide. With its beginnings in the Biochemistry/Microbiology department at the University of Victoria, IPA expanded and built a new Hybridoma Facility, at the Vancouver Island Technology Park (VITP) in 2005.

Robert Beecroft, Chief Technical Officer and Founder, has implemented 3 key methodologies that have allowed IPA to be set apart from other antibody companies: 1) the Rapid Prime immunization strategy in mice; 2) Single-Step cloning for HAT selection of hybridomas and 3) RMAT –recombinant monoclonal antibody technology for the generation of rabbit monoclonal antibodies.

Technology

IPA uses proprietary and innovative inoculation and cloning technologies and established expertise to produce mAbs significantly faster than traditional methods of antibody production and has used these capacities to produce hundreds of mAbs, many of which are now being sold commercially through industry partners.

Operations

We have an in-house animal care unit, tissue culture facility and a molecular facility.

                                                       

 

A Personalized Approach to Your Most Difficult Projects

Project personalization starts with a dedicated Principal or Senior Scientist as your project lead; to help manage your project today as well as all of your future pipeline custom mAb development needs. Taking this approach enables us to rapidly build a constructive professional working relationship based upon project data driven communications and collaboration. Our belief in actively investing in our client relationships has greatly aided us and our clients grow over the past 25 years through successful, high quality project outcomes.

Proprietary Technologies to Rapidly Provide High Affinity mAbs

IPA uses proprietary and innovative inoculation and cloning technologies, as well as established expertise, to produce mAbs significantly faster than traditional methods of antibody production. With these capacities IPA has produced hundreds of mAbs, many of which are now being sold commercially through industry partners.

Adaptive Lab Operations Allowing for In Process Project Add-Ons

To service your most difficult projects, our lab operations have been structured around providing project flexibility with the ability for in-process project add-ons. Additionally, we have established specific client touchpoints to review preliminary project results and discuss any changes to project direction to help clients get the most out of their investment.

 

 

OmniMouseOmniRatOmniFlic

OmniAb® Service Provider

ImmunoPrecise is pleased to be a new preferred OmniAb® service provider. We have successfully adapted our Rapid Prime immunization strategy and our antibody development platform to OmniAb® animals for delivery of a diverse repertoire of antigen-specific antibodies with an industry-leading timeframe.

The Platform

Ligand Pharmaceutical’s OmniAb® transgenic rodents – OmniRat®, OmniMouse® and OmniFlic® – produce highly diversified antibody repertoires and offer accelerated discovery of fully human antibodies that are naturally optimized in vivo for manufacturability, therapeutic efficacy and reduced immunogenicity.

ImmunoPrecise’s proprietary immunization and development platform works directly with OmniAb® animals for human antibody discovery. Based on hybridoma technology, our platform includes isolation of clones from semi-solid medium.

We have the capability to perform a variety of immunization protocols with OmniAb® animals including protein, peptide, DNA, or whole cell immunization.

By establishing a collaborative workflow between the client, Ligand, and the breeding facility, we can take a project from a target sequence to immunization, fusion, screening and delivery of the desired antibody.

Let our team of experienced scientists work with you to customize your human antibody development campaign.

Hybridoma Development

We custom develop mAbs to an array of antigens including peptides, modified peptides, recombinant proteins, DNA plasmids, small molecules and anti-idiotypic antibodies.

Mouse Rapid Prime Monoclonal Antibody Development

Rapid Prime is ImmunoPrecise’s proprietary custom monoclonal antibody development service. This rapid immunization strategy saves weeks in development time. When coupled with our Single-Step cloning procedure, positive hybridoma cell lines are identified in 65 days. This rapid immunization procedure does not compromise on affinity. It consistently generates large numbers of IgG clones specific for antigen. Click here for more Rapid Prime information.

This popular choice for antibody development can be paired with 2 standard method mice which serve as a contingency plan. Contact us and ask about our “Rapid Prime plus Contingency” antibody design.

Standard Method Monoclonal Antibody Development in Mice & Rats

ImmunoPrecise’s custom standard monoclonal antibody development service is the gold standard in antibody development. Intraperitoneal injections and a choice of adjuvant is available to suit the client’s specific needs. When this traditional immunization procedure is coupled with our Single-Step cloning method, weeks are shaved off the timeline of monoclonal development. Click here for more Standard Method information.

For more information please click here 

 

Rabbit Monoclonal Antibodies

 

Recombinant

 

ImmunoPrecise is excited to offer custom Rabbit Monoclonal Antibody development service using RMAT (Recombinant Monoclonal Antibody Technology). This proprietary technology screens the immune repertoire of the rabbit creating the power to select the desired antibody directly from B cells.

The RMAT Advantage

High affinity antibodies without the traditional cell fusion step; avoids stability issues commonly associated with hybridomas
Recombinant antibody ensures preservation of genetic information
Both a monoclonal and polyclonal end product
Utilization of rabbit immune system to generate antibodies against different epitopes on the same antigen

For more infromation please click here 

 

Recombinant Protein Expression and Production

ImmunoPrecise is excited to offer recombinant protein expression and production services.  Our proprietary expression technology is designed to deliver fast and large-scale production of (mammalian) recombinant proteins and antibodies for research and pre-clinical applications.

Recombinant Protein Services

Transient mammalian recombinant protein production in HEK293E and HEK293ES (N-linked glycosylation deficient) cells using the r-PEX platform.
Stable protein production in HEK293E and HEK293ES cells.
Recombinant protein production in Escherichia coli or Pichia pastoris.
Purification of (recombinant) proteins.
Recombinant antibody development and production via the r-Ab platform.

For more information please click here 

Cryostorage

Cryostorage

In the event of an emergency, it is crucial to have a secondary stock of your valuable biological materials stored at an alternative location. ImmunoPrecise provides you with a secure, off-site storage facility to safeguard your assets.  We have the capability to store cell lines, tissues, RNA, DNA, plasmid constructs, antibodies, and many other biological materials.

Storage Options

+4°C
-20°C
-80°C
-196°C (Liquid Nitrogen, LN­2)

For more information please click here 

Hybridoma Sequencing

ImmunoProtect™: Hybridoma Sequencing

Your monoclonal antibody (mAb) is extremely valuable, but hybridoma cell lines can become unstable over time and can stop secreting antibody. With ImmunoProtect™, the DNA sequence of your antibody will be determined and can be used to express your mAb recombinantly should your hybridoma cell line become unstable.

Click here for further information 

For more information on all the services offered please click here

For information on products please click here 

 

 

Robert Beecroft
INTERIM CHIEF EXECUTIVE OFFICER, CHIEF TECHNICAL OFFICER AND DIRECTOR

Robert Beecroft is the founder and Chief Technical Officer of ImmunoPrecise and previously served as its Chief Executive Officer and President. Mr. Beecroft has over 25 years’ experience in the development of innovative and proprietary methods for the production of monoclonal and polyclonal antibodies and peptides. Mr. Beecroft has a B.Sc. in Microbiology from University of Victoria and has been involved in over 15 Research Projects over the course of the last 25 years and been an instructor for graduate students at the University of Victoria on the use and production of monoclonal antibodies for over 13 years.  In 2015, Mr. Beecroft was the recipient of the UVic Distinguished Alumni Award for the Faculty of Science, in recognition for being the Founder of ImmunoPrecise Antibodies Ltd.

James Kuo, MD, MBA
INTERIM PRESIDENT AND CHAIRMAN

Dr. James Kuo brings considerable global life science business experience to ImmunoPrecise. Currently, he serves as Chief Executive Officer of the Finnish biotechnology company, FIT Biotech. He has also been Chairman and Chief Executive Officer of Synthetic Biologics and BioMicro Systems and Chief Executive Officer of Discovery Laboratories. In addition to these senior biotech leadership roles, Dr. Kuo has been head of business development at Myriad Genetics and Associate Director of Corporate Licensing and Development at Pfizer. He has further served as Managing Director of HealthCare Ventures, a $378 million venture capital fund, and is presently Managing Director at Athena Bioventures in La Jolla, CA. He is also a founder and Chairman of Monarch Labs. Dr. Kuo received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. He received his BA in molecular biology from Haverford College.

Deanna Dryhurst
CHIEF SCIENTIFIC OFFICER

Dr. Dryhurst has been with ImmunoPrecise since 2010. She received an NSERC Industrial Research and Development Postdoctoral Fellowship to work on a platform for rabbit monoclonal antibody development at ImmunoPrecise Antibodies. Rabbit monoclonal antibodies are now a key part of what ImmunoPrecise provides to its clients. She is currently in charge of R&D at ImmunoPrecise where she is responsible for prioritization of research projects, alignment with corporate strategy and developing new product introductions. She received her B.Sc. in Biology, and her Ph.D. in Biochemistry and Molecular Biology from the University of Victoria.

Teri Otto
VP, MARKETING AND SALES SUPPORT

Teri Otto joined ImmunoPrecise in 1997 as a co-op student and continued as a fulltime employee upon graduation in 2000. She began as a technician and animal care manager. She has been a key part of developing ImmunoPrecise’s successful laboratory operations and antibody engineering capabilities, particularly in the area of mouse hybridomas. Ms. Otto holds a B.Sc. (with distinction) from University of Victoria in Microbiology and Associate Degrees in Psychology, Bio Chemistry, and Applied Chemistry from Camosum College in Victoria, BC.

Kevin Wong
VICE PRESIDENT OF CORPORATE SERVICES

Dr. Kevin Wong has served as President of ImmunoPrecise and Vice President of Corporate Services since joining the company in 2013. Dr. Wong has previous experience working in both industry and academic settings. He managed the laboratory operations for Protox Therapeutics for nine years prior to joining ImmunoPrecise. Dr. Wong spent six years at Cambridge University as a Research Associate in both the Departments of Biochemistry and Pathology, as well as two years as a Research Associate at University of Ottawa Department of Cellular and Molecular Medicine. Dr. Wong graduated from the University of Victoria with a Ph.D. in Biochemistry. Dr. Wong has been published in more than a dozen peer-reviewed articles in journals of biological sciences.

Address

ImmunoPrecise Antibodies Ltd.
Vancouver Island Technology Park
Unit 3204-4464 Markham Street
Victoria, British Columbia,
V8Z 7X8, Canada

Toll Free (North America): 1-800-620-4187

Tel: +1-250-483-0308
Fax: +1-250-483-0309

Investor Relations

For investor inquiries please contact:

Contact Financial,
Rob Gamley,
604-689-7422,
[email protected]

Immunoprecise Antibodies Ltd Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use